Relationships between the endothelin and nitric oxide pathways

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 3, 1999, Pages 247-252

  Warner, Timothy D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Blood pressure; Endothelin 1; Nitric oxide; Smooth muscle cell

Indexed keywords

ENDOTHELIN; NITRIC OXIDE;

BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CONFERENCE PAPER; ENDOTHELIUM CELL; HYPERTENSION; MEDIATOR RELEASE; NEGATIVE FEEDBACK; REPERFUSION INJURY; SUBARACHNOID HEMORRHAGE; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ENDOTHELIN-1; HUMANS; NITRIC OXIDE;

EID: 0032987753     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03025.x     Document Type: Conference Paper

References (71)

1. 1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
2. 2. Michel T, Feron O. Nitric oxide synthases: Which, where, how, and why? J. Clin. Invest. 1997; 100: 2146-52.
3. 3. Stamler JS, Simon DI, Osborne JA et al. s-Nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc. Natl Acad. Sci. USA 1992; 89: 444-8.
4. 4. de Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl Acad. Sci. USA 1988; 85: 2334-8.
5. 5. D'Orleans-Juste P, Mitchell JA, Wood EG, Hecker M, Vane JR. Comparison of the release of vasoactive factors from venous and arterial cultured endothelial cells. Can. J. Physiol. Pharmacol. 1992; 70: 687-94.
6. 6. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227: 1477-9.
7. 7. Carosi JA, McIntire LV, Eskin SG. Modulation of secretion of vaso-active materials from human and bovine endothelial cells by cyclic strain. Biotechnol. Bioeng. 1994; 43: 615-21.
8. 8. Korenaga R, Ando J, Tsuboi H, Yang W, Sakuma I, Toyo-oka T, Kamiya A. Laminar flow stimulates ATP-and shear stress-dependent nitric oxide production in cultured bovine endothelial cells. Biochem. Biophys. Res. Commun. 1994; 198: 213-19.
9. 9. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 1994; 269: 18275-8.
10. 10. Xu D, Emoto N, Giaid A et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-85.
11. 11. Schweizer A, Valdenaire O, Nelbock P et al. Human endothelin-converting enzyme (ECE-1): Three isoforms with distinct subcellular localizations. Biochem. J. 1997; 328: 871-7.
12. 12. Macarthur H, Warner TD, Wood EG, Corder R, Vane JR. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem. Biophys. Res. Commun. 1994; 200: 395-400.
13. 13. Milner P, Bodin P, Loesch A, Burnstock G. Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow. Biochem. Biophys. Res. Commun. 1990; 170: 649-56.
14. 14. Vemulapalli S, Chiu PJS, Griscti K, Brown A, Kurowski S, Sybertz EJ. Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats. Eur. J. Pharmacol. 1994; 257: 95-102.
15. 15. Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR. Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc. Natl Acad. Sci. USA 1995; 92: 2691-5.
16. 16. Warner TD, Klemm P. What turns on the endothelins? Inflamm. Res. 1996; 45: 51-3.
17. A receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. Life Sci. 1997; 60: PL271-6.
18. 18. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
19. 19. Warner TD. Characterization of endothelin synthetic pathways and receptor subtypes: Physiological and pathophysiological implications. Eur. Heart. J. 1993; 14 (Suppl. 1): 42-7.
20. 20. Boulanger CM, Lüscher TF. Release of endothelin from the porcine aorta: Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 1990; 85: 587-90.
21. 21. Warner TD, Schmidt HHHW, Murad F. Interactions of endothelin and EDRF in bovine native endothelial cells: Selective effects of endothelin-3. Am. J. Physiol. 1992; 262: H1600-5.
22. 22. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl Acad. Sci. USA 1989; 86: 3375-8.
23. G-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br. J. Pharmacol. 1990; 101: 10-12.
24. 24. Warner TD, Mitchell JA, Sheng H, Murad F. Effects of cyclic GMP on smooth muscle relaxation. Adv. Pharmacol. 1994; 26: 171-94.
25. 25. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2.
26. 26. Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-5.
27. 125I]endothelin-1 binding data. Life Sci. 1992; 51: 1869-76.
28. 28. Marsault R, Feolde E, Frelin C. Receptor externalization determines sustained contractile responses to endothelin-1 in the rat aorta. Am. J. Physiol. 1993; 264: C687-93.
29. 29. Warner TD, Allcock GH, Vane JR. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists. BQ-123 and PD 145065. Br. J. Pharmacol. 1994; 112: 207-13.
30. 30. Haynes WG, Ferro CE, Webb DJ. Physiologic role of endothelin in maintenance of vascular tone in humans. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 3): S183-5.
31. 31. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-70.
32. 32. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J. Hypertens. 1996; 14: 975-81.
33. A endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation 1997; 95: 240-4.
34. 34. Redmond EM, Cahill PA, Hodges R, Zhang S, Sitzmann JV. Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells. J. Cell. Physiol. 1996; 166: 469-79.
35. 35. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 1987; 148: 1482-9.
36. 36. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-8.
37. 37. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial celts. Proc. Natl Acad. Sci. USA 1988; 85: 2800-4.
38. 38. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368: 850-3.
39. 39. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 1991; 88: 4651-5.
40. 40. Ma X, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 1993; 72: 403-12.
41. 41. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am. J. Physiol. 1988; 255: H1269-75.
42. 42. Jaeschke H, Farhood A, Smith CW. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J. 1990; 4: 3355-9.
43. 43. Lefer AM, Ma X. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler. Thromb. 1993; 13: 771-6.
44. 44. Niu X-F, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ. Res. 1994; 74: 1133-40.
45. 2-analogues and an NO (EDRF)-donor: A comparison between platelets of healthy and diabetic subjects. Platelets 1994; 5: 45-52.
46. 46. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 1994; 46: 325-415.
47. 47. Thiemerman C, Lidbury PS, Thomas GR, Vane JR. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anaesthetized rabbit. J. Cardiovasc. Pharmacol. 1989; 13 (Suppl. 5): S138-41.
48. 111indium labelled platelets. Br. J. Pharmacol. 1990; 99: 303-8.
49. 49. Filep JG, Herman F, Battistini B, Chabrier P-E, Braquet P, Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs: Role for prostacyclin. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 7): S216-18.
50. 50. Korbut R, Lidbury PS, Thomas GR, Vane JR. Fibrinolytic activity of endothelin-3. Thromb. Res. 1989; 55: 797-9.
51. 51. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem. Biophys. Res. Commun. 1992; 189: 994-1000.
52. 52. Bath PM, Mayston S, Martin JF. Endothelin and PDGF do not stimulate peripheral blood monocyte chemotaxis, adhesion to endothelium, and superoxide production. Exp. Cell. Res. 1990; 187: 339-42.
53. 53. Filep JG, Sirois MG, Rousseau A, Fournier A, Sirois P. Effects of endothelin-1 on vascular permeability in the conscious rat: Interactions with platelet activating factor. Br. J. Pharmacol. 1991; 104: 797-804.
54. 54. Valentin JP, Gardener DG, Wiedemann E, Humphreys MH. Modulation of endothelin effects on blood pressure and hematocrit by atrial natriuretic factor. Hypertension 1991; 17: 864-9.
55. 55. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: Role of renin and vascular hypertrophy. J. Hypertens. 1993; 11: 1083-8.
56. 56. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries of the rat. Clin. Exp. Hypertens. 1993; 15: 527-37.
57. 57. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 1994; 14: 753-9.
58. 58. Barrett ML, Willis AL, Vane JR. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents Actions 1989; 27: 488-91.
59. 59. Garg UC, Hassid A. Nitric-oxide generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989; 83: 1774-7.
60. 60. Vane JR, Botting RM. Impact of risk factors on the endothelium. Cardiovasc. Risk Factors 1994; 4: 108-21.
61. 61. Douglas SA, Ohlstein EH. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J. Cardiovasc. Pharmacol. 1993; 22 (Suppl. 8): S371-3.
62. 62. Douglas SA, Louden C, Vickery-Clarke LM et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ. Res. 1994; 75: 190-7.
63. 63. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem. Biophys. Res. Commun. 1993; 191: 1081-8.
64. 64. Wilcox JN, Subramanian RR, Sundell CL et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler. Thromb. Biol. 1997; 17: 2479-88.
65. 65. Douglas SA, Vickery-Clarke LM, Ohlstein EH. Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction. Eur. J. Pharmacol. 1994; 255: 81-9.
66. 66. Corder R, Carrier M, Khan N, Klemm P, Vane JR. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 3): S56-8.
67. 67. Woods M, Bishop-Bailey D, Pepper JR, Evans TW, Mitchell JA, Warner TD. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from internal mammary artery and saphenous vein smooth muscle cells. J. Cardiovasc. Pharmacol. 1998; 31 (Suppl. 1): S348-50.
68. 68. Ruetten H, Thiemermann C. Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br. J. Pharmacol. 1996; 118: 198-204.
69. 69. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab. Invest. 1993; 68: 600-28.
70. 70. Huggins JP, Pelton JT, Miller RC. The structure and specificity of endothelin receptors: Their importance in physiology and medicine. Pharmacol. Ther. 1993; 59: 55-123.
71. 71. Warner TD, Battistini B, Doherty AM, Corder R. Endothelin receptor antagonists: Actions and rationale for their development. Biochem. Pharmacol. 1994; 48: 625-35.